The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Medical Progress
PreviousPrevious
Volume 346:580-590 February 21, 2002 Number 8
NextNext

Strategies to Improve Long-Term Outcomes after Renal Transplantation
Manuel Pascual, M.D., Tom Theruvath, M.D., Tatsuo Kawai, M.D., Nina Tolkoff-Rubin, M.D., and A. Benedict Cosimi, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
After cyclosporine and muromonab-CD3 (OKT3 monoclonal antibody) were introduced into clinical practice in the early 1980s, one-year survival rates for renal allografts improved from approximately 60 percent to between 80 and 90 percent.1,2,3 However, the incidence of acute rejection in the first six months after transplantation remained high; approximately half the recipients had at least one episode of acute rejection. In the 1990s, the introduction of new immunosuppressive agents led to a decrease in the incidence of acute rejection.4 Although long-term allograft survival has improved,1 chronic rejection and death with a functioning graft remain leading causes of the late loss . . . [Full Text of this Article]

The Problem of Late Allograft Loss

Chronic Rejection in Renal Transplantation

Death with a Functioning Allograft

Current Strategies to Prevent Late Allograft Loss

Perioperative Management and HLA Matching

Pharmacologic Prevention of Acute Rejection

            Tacrolimus

            Mycophenolate Mofetil

            Sirolimus

            Monoclonal Antibodies against the Interleukin-2 Receptor

Treatment of Severe or Refractory Acute Rejection

Optimal Dose of Calcineurin Inhibitors beyond the First Year after Transplantation

Discontinuation of Corticosteroids

Treatment of Hypertension and Hyperlipidemia

Future Strategies to Minimize Late Allograft Loss

Avoidance of Calcineurin Inhibitors or Corticosteroids

Hyporesponsiveness, or the Induction of Tolerance

Conclusions


Source Information

From the Renal Unit (M.P., N.T.-R.) and the Transplantation Unit (M.P., T.T., T.K., N.T.-R., A.B.C.), Departments of Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston.

Address reprint requests to Dr. Pascual at the Renal Unit, Box MZ 70, Massachusetts General Hospital, Boston, MA 02114, or at mpascual@partners.org.

References


Related Letters:

Strategies to Improve Outcomes after Renal Transplantation
Rigatto C., Parfrey P., Montori V. M., Basu A., Kudva Y. C., Baum C. L., McGee A. P., Friedman A., Friedman A., Pascual M., Tolkoff-Rubin N., Cosimi A. B.
Extract | Full Text | PDF  
N Engl J Med 2002; 346:2089-2092, Jun 27, 2002. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.